drugset / Trial / NCT03654001

ALBumin Italian Outcome Septic Shock-BALANCED Trial (ALBIOSS-BALANCED)

NCT03654001

RandomizedFactorialOpen-labelTreatment

Summary

Septic shock is a devastating condition often observed in ICU. It is characterized by pro-inflammatory and immune responses, organ failures, high incidence of AKI and lethality. Fluid resuscitation is pivotal as supportive therapy. At present, there are no effective therapies to improve survival of such clinical condition, often characterized by a mortality as high as 40% during the first 90 days from diagnosis. This project proposes a large 2-by-2 factorial randomized clinical trial testing the efficacy of albumin and the low- chloride balanced crystalloid solutions (either Ringer Lactate, Ringer Acetate, or Crystalsol - BAL) in septic shock. The investigators have recently concluded a multicenter, randomized trial, the ALBIOS trial, in which, in a post-hoc analysis, albumin, in addition to crystalloids, reduced 90-day mortality in patients with septic shock, as compared to crystalloids alone (Caironi P et al, 2014). Crystalloids with supra-physiological chloride content may deteriorate renal perfusion, increasing the risk of acute kidney injury (AKI) and mortality.

Timeline

Start
2019-05-07
Primary completion
2024-10-31
Completion
2025-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Albumin Protein / enzyme biologic 400 ml
Subject Crystalsol Other / unclassified
Subject Ringer acetate Other / unclassified
Subject Ringer lactate Other / unclassified